Physician profile
Lydia Zuser
NPI 1437150505
$10,768.24
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,141 · 2020: $1,254 · 2021: $2,645 · 2022: $2,313 · 2023: $2,282 · 2024: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,316 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,316.22 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,354.49 | 2019-2023 | |
| Lilly USA, LLC | $1,107.13 | 2019-2023 | Jardiance, Emgality, Mounjaro |
| Abbvie INC. | $984.63 | 2019-2024 | Vraylar, Qulipta, Viberzi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $946.12 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $831.69 | 2019-2023 | Breztri |
| Astellas Pharma US INC | $566.40 | 2019-2023 | Veozah, Myrbetriq |
| Novo Nordisk INC | $472.75 | 2019-2024 | Rybelsus, Saxenda, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $384.69 | 2019-2023 | Trintellix, Gattex |
| Bayer Healthcare Pharmaceuticals INC. | $323.24 | 2021-2024 | |
| Sunovion Pharmaceuticals INC. | $319.79 | 2021-2022 | |
| Glaxosmithkline, LLC. | $309.48 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $306.36 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $302.95 | 2019-2023 | Ajovy |
| Vanda Pharmaceuticals INC. | $277.44 | 2019-2023 | Hetlioz |
| Sanofi-Aventis U.S. LLC | $276.35 | 2019-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lydia Zuser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.